Bayer lures Novartis’ Reinhardt for top healthcare post
pharmafile | April 22, 2010 | Appointment | Research and Development, Sales and Marketing | Bayer, appointment, research and development, sales and marketing
German pharma company Bayer has ended its search for someone to replace healthcare chief executive Arthur Higgins, appointing Dr Jörg Reinhardt to the role.
Currently chief operating officer at Novartis, Dr Reinhardt will take up post on 15 August, and will also serve as chairman of the board of management and the executive committee of Bayer Healthcare.
Until then Bayer’s chairman-designate Dr Marijn Dekkers will head up Bayer Healthcare on a temporary basis.
“Dr Reinhardt is an acknowledged expert with many years of experience in the health care industry,” commented Werner Wenning, chairman of the Board of Management of Bayer. “We are convinced of his ability to provide a decisive impetus to our global HealthCare business and further expand our strong competitive positions.”
The 54-year old Dr Reinhardt, a German national, began his pharma career with Sandoz, a predecessor of Novartis, in 1982, holding various R&D managerial positions.
He was appointed head of corporate development in 1994 and, after the formation of Novartis in 1996, served as head of preclinical development and project management before being appointed global head of development in 1999.
Before taken on the role of chief operating officer he headed up the vaccines and diagnostics division in the US.
Current healthcare chief executive Arthur Higgins will leave the company as planned on April 30.
“Over the past years, Arthur Higgins has made a decisive contribution to the restructuring and strengthening of Bayer HealthCare and has set new trends,” said Wenning. “We thank him for his great commitment and wish him well for the future.”
Related Content
Evotec and Bayer announce new kidney disease study
Evotec and Bayer have announced the initiation of a phase 2 clinical study in kidney …
PlasmidFactory founder Dr. Martin Schleef honoured with the NRW Innovation Award 2025
The founder and long-standing CEO of PlasmidFactory, Dr. Martin Schleef, was honoured in Düsseldorf with …
AAX Biotech announces collaboration for cardiovascular antibody therapy
Swedish biotech firm AAX Biotech has entered a new collaboration focused on the development of …
